Solara Active Pharma Sciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.00×	1.00×	1.00×	1.16×	0.50×
	0.29×	−0.09×	0.01×	2.46×	−1.97×
	8.4%	6.4%	8.3%	−15.4%	1.6%
	0.60×	0.60×	0.56×	0.49×	0.49×
	1.71×	1.86×	2.03×	2.51×	1.93×
	2.5%	−0.6%	0.0%	−54.1%	−1.5%
	−0.6%	−0.6%	0.1%	−46.6%	−1.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health

₹ CrorePeersINDSWFTLAB DCAL SMSPHARMA HIKAL PANACEABIO SAIPARENT INDOCO UNICHEMLABMcap ₹2,910 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.50	1.16	1.00	1.00	1.00
Interest Burden (Pretax/EBIT) ×	-1.97	2.46	0.01	-0.09	0.29
EBIT Margin %	1.57	-15.40	8.34	6.36	8.39
Asset Turnover ×	0.49	0.49	0.56	0.60	0.60
Financial Leverage (Assets/Equity) ×	1.93	2.51	2.03	1.86	1.71
ROE (5-step product, year-end total equity) %	-1.46	-54.10	0.05	-0.60	2.46
ROE (owners' profit / average owners' equity) %	-1.47	-46.62	0.05	-0.63	-0.63

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.